References
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular
outcomes, and mortality in type 2 diabetes. N Engl J Med.
2015;373(22):2117-28.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal
outcomes in type 2 diabetes and nephropathy. N Engl J Med.
2019;380(24):2295-306.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in
patients with chronic kidney disease. N Engl J Med.
2020;383(15):1436-46.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes
with Empagliflozin in heart failure. N Engl J Med.
2020;383(15):1413-24.
- Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic
ketoacidosis. Br Med J. 1973;2(5866):578-80.
- Committee on the proper Use of SGLT2 inhibitors. Recommendations on
the Proper Use of SGLT2 Inhibitors. Diabetol Int. 11(1):1-5.
- Drug safety announcement. FDA warns that SGLT2 inhibitors for diabetes
may result in a serious condition of too much acid in the blood.
https://www.fda.gov/downloads/drugs/drugsafety/ucm446954.pdf; 2021.
Accessed April 16, 2022.
- Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults
with diabetes or prediabetes: a consensus report. Diabetes Care.
2019;42(5):731-54.
- Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises
in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-43.
- Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a
review. Curr Diabetes Rev. 2017;13(3):315-21.
- Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose
co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-9.
- Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with
SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res
Rev. 2017;33(8): doi:10.1002/dmrr.2924
- Somagutta MR, Agadi K, Hange N, et al. Euglycemic diabetic
ketoacidosis and sodium-glucose cotransporter-2 inhibitors: a focused
review of pathophysiology, risk factors, and triggers. Cureus.
2021;13(3): doi:10.7759/cureus.13665.
- Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic
ketoacidosis caused by sodium glucose cotransporter 2 inhibitors: a
Case Report. Ann Intern Med. 2016;165(7):530-2.
- Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk
in patients with type 1 diabetes on adjunctive treatment with SGLT
inhibitors: a STICH protocol. Diabetes Technol Ther. 2018;20(9):571-5.